LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Pourdowlat, Guitti"
  2. AU="Kurskoy Аndrey Yu."
  3. AU="Kuo, Albert"
  4. AU="Haustraete, Eglantine"
  5. AU="Li, Ziying"
  6. AU="Kimura, Kasane"
  7. AU="Gleeson, Sarah"
  8. AU="Hong, Ki Hyun"
  9. AU="Adalbert, V’kovski Philip"
  10. AU="Witte, Martin D"
  11. AU=Sun Yuan
  12. AU=Khan Zeashan Hameed AU=Khan Zeashan Hameed
  13. AU=Andrade D M
  14. AU="Miyata, Fumika"
  15. AU="Ahmad Rizal"
  16. AU="Aponte, Nelson"
  17. AU=Manfredonia Ilaria
  18. AU="Ryu, Jae Sung"
  19. AU="Lo, Bernard"
  20. AU="Pandya, Hardi"
  21. AU="Evans, J Anthony"
  22. AU="Chang, Hanxuan" AU="Chang, Hanxuan"
  23. AU="Bellamy, Kyle" AU="Bellamy, Kyle"
  24. AU="Jensen, Kara L"
  25. AU=Wang Yun
  26. AU=Seimiya H
  27. AU="Victor Babos, Diego"
  28. AU="Giuseppe Sergi"
  29. AU="Nackers, Elke"
  30. AU=Grobler Chistine
  31. AU="Norman H. L. Chiu"
  32. AU="Ioannis Politis"
  33. AU="Scott Nugent"
  34. AU="Sepideh MONSEF"
  35. AU="Wang, Zhaoqi"

Suchergebnis

Treffer 1 - 10 von insgesamt 35

Suchoptionen

  1. Artikel: Local Administration of Sodium Bicarbonate for Preventing COVID-19 Associated Mucormycosis.

    Pourdowlat, Guitti / Pourabdollah, Mihan / Sharifynia, Somayeh / Saghafi, Fatemeh

    Tanaffos

    2024  Band 22, Heft 3, Seite(n) 337–340

    Abstract: Background: One important complication of the coronavirus disease 2019 (COVID-19) is COVID Associated Mucormycosis (CAM), especially in patients with conditions such as diabetes and in immunosuppressed patients. Systemic acidosis, hyperglycemia, and ... ...

    Abstract Background: One important complication of the coronavirus disease 2019 (COVID-19) is COVID Associated Mucormycosis (CAM), especially in patients with conditions such as diabetes and in immunosuppressed patients. Systemic acidosis, hyperglycemia, and other biochemical factors such as free iron and β-hydroxybutyrate (BHB) can play a role in this complication.
    Materials and methods: Rhizopus oryzae
    Results: We found that the minimum inhibitory and fungicidal concentrations are at 1.05 % and 2.1 % respectively. Therefore, the minimum concentration is 2% sodium bicarbonate, which requires achieving the desired environmental pH for fungal inhibition and fungicidal effects.
    Conclusion: Regulation of systemic acidosis by sodium bicarbonate could be used to decrease the chance of mucormycosis. In addition, According to our study and some others, an alkaline environment can prevent fungal growth. We found that a minimum concentration of 2% sodium bicarbonate is required to achieve the desired mucosal pH to inhibit the fungus. Therefore, sodium bicarbonate inhalation, as a cost-effective and well-tolerated medicine, is a good candidate for the prevention of mucormycosis. In this regard, extensive clinical and laboratory research is needed to achieve more accurate doses and appropriate administration intervals.
    Sprache Englisch
    Erscheinungsdatum 2024-02-29
    Erscheinungsland Iran
    Dokumenttyp Journal Article
    ZDB-ID 2233372-1
    ISSN 1735-0344
    ISSN 1735-0344
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Magnesium Sulfate

    Pooransari, Parichehr / Pourdowlat, Guitti

    Advanced Journal of Emergency Medicine; In press ; 2588-400X ; 10.22114/ajem.v0i0

    A Potential Adjuvant Treatment on COVID-19

    2020  

    Abstract: COVID-19 has currently become a major global health problem. Due to novelty and high morbidity and mortality, there are some important medical challenges to achieve proper management and treatment of the disease. Different pharmaceutical categories have ... ...

    Abstract COVID-19 has currently become a major global health problem. Due to novelty and high morbidity and mortality, there are some important medical challenges to achieve proper management and treatment of the disease. Different pharmaceutical categories have been candidate for viral or cytokine phase control, and in this regard many clinical trials are underway to obtain evidences and acceptable results. One of these compounds is magnesium (Mg) sulfate which may have potential therapeutic effect on the cytokine phase of COVID-19. Mg compounds have long been used in practice under various indications and purposes as supplemental compounds, electrolyte regulation and also prevention of drugs side effects. In addition, the effectiveness of Mg sulfate in controlling asthma attacks, gynecological cases and pre-natalogical problems has also been proven. Herein we briefly reviewed immunomodulatory and respiratory effects of Mg and its potential benefits in COVID-19 treatment. Mg sulfate can be used both systemically and by inhalation, but nebulizer route has potential effect on rapid onset of action on respiratory system and reduced incidence of systemic side effects. To the best of our knowledge, in COVID-19 patients, as other viral infections, airway hyper-reactiveness can be overrepresented. In this regard ventilation improvement and reducing of airway resistance should be considered. Some bronchodilators, such as β2-agonists and anti-muscarinic agents used to relieve these symptoms. Another option has provided for hospitalized patients, is nebulized Mg sulfate. It has been suggested in the literature that Mg sulfate can cause bronchodilation in asthmatic patients by various mechanisms, including by inhibition of calcium influx into the cytosol, prevention of acetylcholine secretion, inhibition of histamine release; and finally, by β2-receptor affinity enhancement, increases bronchodilator effect of β2-agonists. On the other hand, according to some researches, low Mg level is associated with increased inflammatory response. in vitro studies showed that short-term exposure to Mg sulfate without affecting on viability and function of phagocytes, diminished cytokine gene and protein expression, and consequently could reduce production of TNF-α and IL-6 from neonatal monocytes. Moreover, Mg sulfate can reduce the level of interleukin 1β, that is a potent pro-inflammatory cytokine. Another study of the anti-inflammatory effect of Mg compounds showed that neutralized Mg ions can convert THP-1-derived macrophages to the M2 phenotype (anti-inflammatory macrophages), thereby reduce the production of inflammatory cytokines and enhance the secretion of anti-inflammatory cytokines. As well as, according to in vitro and in vivo studies, Mg sulfate significantly reduces baseline level along with LPS-stimulated cytokine production. Altogether, given that the cytokine phase of COVID-19 plays a very significant role in patient morbidity and mortality, therefore proper management and control of this stage of the disease is important on rescuing patients. It seems that, administration of Mg compounds as an adjuvant treatment may improve this condition of disease. Our preliminary experiences indicated the potential positive effects of Mg sulfate on the improvement process in covid-19. However, in order to achieve more accurate and reliable results, adequate randomized clinical trials are needed. It should be considered that intravenous administration of this drug can be performed only in the intensive care unit (ICU) and or under close observation, but the Inhaler form does not require close monitoring. Moreover, oral Mg supplementation in outpatients may also reduce the inflammatory response in COVID-19
    Schlagwörter covid19
    Thema/Rubrik (Code) 610
    Sprache Englisch
    Erscheinungsdatum 2020-07-29
    Verlag Tehran University of Medical Sciences
    Erscheinungsland ir
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: The effectiveness of relaxation training in the quality of life and anxiety of patients with asthma.

    Pourdowlat, Guitti / Hejrati, Roghyeh / Lookzadeh, Somayeh

    Advances in respiratory medicine

    2019  Band 87, Heft 3, Seite(n) 146–151

    Abstract: Introduction: With a 5-10% global prevalence, asthma, as a chronic condition which can strongly affect the quality of life of patients and care givers, needs comprehensive approach, including medications and psychological techniques, to get the optimal ... ...

    Abstract Introduction: With a 5-10% global prevalence, asthma, as a chronic condition which can strongly affect the quality of life of patients and care givers, needs comprehensive approach, including medications and psychological techniques, to get the optimal control. This is why the current study aimed to assess the effectiveness of the Papworth method relaxation training among patients with asthma, considering reduced anxiety and improved quality of life.
    Material and methods: Through a randomized controlled trial, 30 patients with asthma 20-45 years of age referring to a tertiary university hospital in Tehran enrolled two study groups, including disease cases and controls. The Papworth method of relaxation was used and was finally assessed for its effectiveness by two questionnaires, namely STAI for anxiety and SF-36 for the quality of life. Pre-test and post-test were done for both groups.
    Results: The scores of the anxiety questionnaire (STAI) before and after the intervention were significantly different, and the mean scores obviously reduced after relaxation training among cases from 102.6 to 79.5. The scores of the QOL grew clearly after relaxation training in the case group from 308.07 to 546.6.
    Conclusions: As an accessory helpful treatment, relaxation training Papworth method sounds to be perfectly able to control stressful conditions in patients with asthma to prevent disease attacks and improve the quality of life. So, psychological teams can be advised to referral centers for asthma in the relevant clinics to help people get training in this regard.
    Mesh-Begriff(e) Adult ; Anxiety/etiology ; Anxiety/psychology ; Anxiety/therapy ; Asthma/complications ; Asthma/psychology ; Asthma/therapy ; Female ; Humans ; Iran ; Male ; Middle Aged ; Muscle Relaxation ; Quality of Life/psychology ; Relaxation Therapy/methods ; Young Adult
    Sprache Englisch
    Erscheinungsdatum 2019-07-04
    Erscheinungsland Poland
    Dokumenttyp Journal Article ; Randomized Controlled Trial
    ZDB-ID 2893877-X
    ISSN 2543-6031 ; 2451-4934
    ISSN (online) 2543-6031
    ISSN 2451-4934
    DOI 10.5603/ARM.2019.0024
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel: Acrocyanosis and digital necrosis are associated with poor prognosis in COVID-19.

    Pourdowlat, Guitti / Naderi, Zohre / Seif, Farhad / Mansouri, Davood / Raji, Hanieh

    Clinical case reports

    2020  Band 8, Heft 12, Seite(n) 2769–2772

    Abstract: Acrocyanosis and digital necrosis, which caused by microangiopathic and immunothrombosis phenomenon, may accompanied by microvascular involvement of other organs. Therefore, this finding can play a prognostic role in covid-19 outcome. ...

    Abstract Acrocyanosis and digital necrosis, which caused by microangiopathic and immunothrombosis phenomenon, may accompanied by microvascular involvement of other organs. Therefore, this finding can play a prognostic role in covid-19 outcome.
    Sprache Englisch
    Erscheinungsdatum 2020-08-30
    Erscheinungsland England
    Dokumenttyp Case Reports
    ZDB-ID 2740234-4
    ISSN 2050-0904
    ISSN 2050-0904
    DOI 10.1002/ccr3.3276
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: Prophylactic Recommendation for Healthcare Workers during COVID-19 Pandemic

    Pourdowlat, Guitti / Panahi, Parnaz / Pooransari, Parichehr / Ghorbani, Fariba

    Advanced Journal of Emergency Medicine

    Schlagwörter covid19
    Verlag WHO
    Dokumenttyp Artikel
    Anmerkung WHO #Covidence: #679449
    Datenquelle COVID19

    Kategorien

  6. Artikel ; Online: Prophylactic Recommendation for Healthcare Workers in COVID-19 Pandemic

    Pourdowlat, Guitti / Panahi, Parnaz / Pooransari, Parichehr / Ghorbani, Fariba

    Advanced Journal of Emergency Medicine; Vol 4 No 2s (2020): COVID-19 ; 2588-400X

    2020  

    Abstract: During COVID-19 pandemic, it seems that healthcare workers (HWs) are more prone to the infection than general population. Indeed, a high viral load atmosphere and infected medical equipment are sources for spreading the disease. Many HWs should care for ... ...

    Abstract During COVID-19 pandemic, it seems that healthcare workers (HWs) are more prone to the infection than general population. Indeed, a high viral load atmosphere and infected medical equipment are sources for spreading the disease. Many HWs should care for patients in the intensive care units (ICUs) which are one of the most contaminated areas. However, despite the adequate protections, HWs are still exposed to the coronavirus. Moreover, some procedures such as tracheal intubation increase the risk of infection. Overall, the probability of contamination in HWs is three times more than that of other people. According to Keshavan et al., about 3300 Chinese HWs have been infected by COVID-19, with a mortality rate of 0.4%. In Iran, we have a large number of affected HWs, with 69 registered deaths until late March 2020. Most of them were young with no previous medical history. So we have to improve protection and plan additional arrangements against COVID-19. There are several mechanisms for the antiviral activity of hydroxychloroquine. This drug is a weak base that concentrates on the intracellular sections including endosome and lysosome; so, viral replication in the phase of fusion and uncoating will be stopped. Also, hydroxychloroquine can change the ACE2 glycosylation and inhibits both S-protein binding and phagocytosis. The last mechanism would be the suppressing effect on cytokine production and the immunomodulatory effect of the drug. Based on in-vitro studies of chloroquine on SARS-CoV-1, its effective role as a prophylactic agent and a post-infection treatment has been raised. According to another cell-culture study, the preventive effect of the drug is estimated to be 24 hours before and 5 hours after the contamination. The weekly dose of 500 mg chloroquine, which is used for malaria prophylaxis, will result in a concentration below the EC50, which is not enough for inhibition of the novel coronavirus. But the minimum dosage, which is used for rheumatoid arthritis treatment (250mg daily) will result in plasma concentrations higher than EC50, which may be sufficient in this regard.Regarding this pharmacokinetics and in-vitro investigations a double-blind, randomized, placebo-controlled trial using chloroquine as a prophylactic agent for SARS-CoV-2 infection is ongoing. The recommended dose is a loading dose of 10 mg/kg from base drug followed by 150 mg daily (250 mg chloroquine phosphate salt). Subsequently, the number of infected patients will be assessed after 3 months. Another running clinical trial is a phase III triple blinded one employing hydroxychloroquine with 200mg daily dose for 60 days and the outcome as well as the rate of symptomatic infected patients will be evaluated. There is also another ongoing study on hydroxychloroquine as a COVID-19 post-exposure prophylactic agent prescribed within 3 days of either a HWs or household contact. The recommended dose is 800mg once, followed by 600 mg during 6 to 8 hours, then 600mg once a day for 4 consecutive days. Finally, the rate and severity of COVID-19 infections are compared. The study could probably show that 200-400mg of hydroxychloroquine per day is a reasonable prophylactic regimen for the exposed HWs. To be more precise, our experience on the rheumatologic patients who tool 200 mg per day hydroxychloroquine, as well as the medical workers who received the same dose for prophylaxis against the novel coronavirus showed that hydroxychloroquine with a 200 mg/day dose can have a relative prophylactic effect on COVID-19. According to our data, the few cases who received 200mg of hydroxychloroquine per day, showed mild to moderate symptoms with no severe manifestations. However, the prophylactic dose of 400mg per day may be accompanied by some drug interactions and adverse effects in the long term; so 200mg of hydroxychloroquine is a rational prophylactic dose for practitioners who are exposed to the high viral load environment.
    Schlagwörter covid19
    Thema/Rubrik (Code) 610
    Sprache Englisch
    Erscheinungsdatum 2020-03-27
    Verlag Tehran University of Medical Sciences
    Erscheinungsland ir
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Prophylactic Recommendation for Healthcare Workers in COVID-19 Pandemic

    Pourdowlat, Guitti / Panahi, Parnaz / Pooransari, Parichehr / Ghorbani, Fariba

    Advanced Journal of Emergency Medicine; Vol 4 No 2s (2020): COVID-19; e39 ; 2588-400X ; 10.22114/ajem.v4i2s

    2020  

    Abstract: During COVID-19 pandemic, it seems that healthcare workers (HWs) are more prone to the infection than general population. Indeed, a high viral load atmosphere and infected medical equipment are sources for spreading the disease. Many HWs should care for ... ...

    Abstract During COVID-19 pandemic, it seems that healthcare workers (HWs) are more prone to the infection than general population. Indeed, a high viral load atmosphere and infected medical equipment are sources for spreading the disease. Many HWs should care for patients in the intensive care units (ICUs) which are one of the most contaminated areas. However, despite the adequate protections, HWs are still exposed to the coronavirus. Moreover, some procedures such as tracheal intubation increase the risk of infection. Overall, the probability of contamination in HWs is three times more than that of other people. According to Keshavan et al., about 3300 Chinese HWs have been infected by COVID-19, with a mortality rate of 0.4%. In Iran, we have a large number of affected HWs, with 69 registered deaths until late March 2020. Most of them were young with no previous medical history. So we have to improve protection and plan additional arrangements against COVID-19. There are several mechanisms for the antiviral activity of hydroxychloroquine. This drug is a weak base that concentrates on the intracellular sections including endosome and lysosome; so, viral replication in the phase of fusion and uncoating will be stopped. Also, hydroxychloroquine can change the ACE2 glycosylation and inhibits both S-protein binding and phagocytosis. The last mechanism would be the suppressing effect on cytokine production and the immunomodulatory effect of the drug. Based on in-vitro studies of chloroquine on SARS-CoV-1, its effective role as a prophylactic agent and a post-infection treatment has been raised. According to another cell-culture study, the preventive effect of the drug is estimated to be 24 hours before and 5 hours after the contamination. The weekly dose of 500 mg chloroquine, which is used for malaria prophylaxis, will result in a concentration below the EC50, which is not enough for inhibition of the novel coronavirus. But the minimum dosage, which is used for rheumatoid arthritis treatment (250mg daily) will result in plasma concentrations higher than EC50, which may be sufficient in this regard.Regarding this pharmacokinetics and in-vitro investigations a double-blind, randomized, placebo-controlled trial using chloroquine as a prophylactic agent for SARS-CoV-2 infection is ongoing. The recommended dose is a loading dose of 10 mg/kg from base drug followed by 150 mg daily (250 mg chloroquine phosphate salt). Subsequently, the number of infected patients will be assessed after 3 months. Another running clinical trial is a phase III triple blinded one employing hydroxychloroquine with 200mg daily dose for 60 days and the outcome as well as the rate of symptomatic infected patients will be evaluated. There is also another ongoing study on hydroxychloroquine as a COVID-19 post-exposure prophylactic agent prescribed within 3 days of either a HWs or household contact. The recommended dose is 800mg once, followed by 600 mg during 6 to 8 hours, then 600mg once a day for 4 consecutive days. Finally, the rate and severity of COVID-19 infections are compared. The study could probably show that 200-400mg of hydroxychloroquine per day is a reasonable prophylactic regimen for the exposed HWs. To be more precise, our experience on the rheumatologic patients who tool 200 mg per day hydroxychloroquine, as well as the medical workers who received the same dose for prophylaxis against the novel coronavirus showed that hydroxychloroquine with a 200 mg/day dose can have a relative prophylactic effect on COVID-19. According to our data, the few cases who received 200mg of hydroxychloroquine per day, showed mild to moderate symptoms with no severe manifestations. However, the prophylactic dose of 400mg per day may be accompanied by some drug interactions and adverse effects in the long term; so 200mg of hydroxychloroquine is a rational prophylactic dose for practitioners who are exposed to the high viral load environment.
    Schlagwörter covid19
    Thema/Rubrik (Code) 610
    Sprache Englisch
    Erscheinungsdatum 2020-03-27
    Verlag Tehran University of Medical Sciences
    Erscheinungsland ir
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  8. Artikel: Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion.

    Mehraban, Zahra / Pourdowlat, Guitti / Mortaz, Esmaeil / Atefeh, Abedini / Ghaforian, Amin R / MalAmir, Mehrdad Dargahi / Bakhtiari, Nima

    Journal of family medicine and primary care

    2022  Band 11, Heft 11, Seite(n) 6843–6847

    Abstract: Background: There are two main causes of exudative effusion including malignancy-induced effusion and tuberculosis. Considering that in reactive ejections, such as tuberculosis-induced effusion, the role of B lymphocytes and in the malignant effusion, ... ...

    Abstract Background: There are two main causes of exudative effusion including malignancy-induced effusion and tuberculosis. Considering that in reactive ejections, such as tuberculosis-induced effusion, the role of B lymphocytes and in the malignant effusion, the role of T lymphocytes are more important, in this study we analyzed the frequency of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON in the pleural and serum samples of patients with exudative lymphocytic-dominant effusion.
    Methods: In total, 73 patients were enrolled in the study by exudative lymphocyte effusion, and finally, 63 patients had definite diagnoses. The patients were sorted into three groups including malignant, tuberculosis, and none. The sample of blood plasma and pleural effusion were collected and CD markers were analyzed using flow cytometry.
    Results: The mean age in the malignancy and tuberculous (TB) groups was 63.16 ± 12 and 52.15 ± 22.62, respectively. There was no significant difference in the frequency of CD8, CD4, and CD16-56 cells in blood samples of patients with tuberculosis and malignancy. Compared to those with tuberculosis, the percentage of CD64 cells was significantly higher in patients with tuberculosis than in malignant subjects. Moreover, a comparison of the frequency of cells with CD8, CD4, CD19, CD64, CD16-56, and CD14 markers in pleural samples showed no significant difference between groups. Other inflammatory factors were also investigated. The erythrocyte sedimentation rate (ESR) value for tuberculosis patients was significantly higher than malignancy. Also, QuantiFERON was positive in 14.3% of malignant patients, and 62.5% of patients with TB, which had a significant difference.
    Conclusion: Considering that there are many confounding variables in the study, such as previous medications, subtypes of
    Sprache Englisch
    Erscheinungsdatum 2022-12-16
    Erscheinungsland India
    Dokumenttyp Journal Article
    ZDB-ID 2735275-4
    ISSN 2278-7135 ; 2249-4863
    ISSN (online) 2278-7135
    ISSN 2249-4863
    DOI 10.4103/jfmpc.jfmpc_2296_21
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel: The youngest surviving COVID-19 patient: A case report.

    Kalani-Moghaddam, Farnaz / Pouralizadeh, Nasim / Pourdowlat, Guitti / Sarfarazi-Moghaddam, Shima / Gharib, Mohammad Hadi / Pakdel, Manizhe

    International journal of surgery case reports

    2022  Band 94, Seite(n) 107065

    Abstract: Introduction and importance: Vertical transmission of the novel coronavirus, known as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has not yet been proven. However, several case reports and case series worldwide, including ours, support ...

    Abstract Introduction and importance: Vertical transmission of the novel coronavirus, known as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has not yet been proven. However, several case reports and case series worldwide, including ours, support this certain type of transmission. Although COVID-19 has been mostly treated supportively, in some cases, including ours, medical treatment seems to be essential.
    Case presentation: Herein, we present a case of a neonate born to an asymptomatic mother with no known history of COVID-19 during pregnancy who was diagnosed as an asymptomatic silent carrier following the confirmation of COVID-19 in her newborn. Although bacterial pneumonia, early-onset sepsis, and meconium aspiration syndrome were the possible differential diagnosis, positive COVID-19 real-time reverse transcriptase-polymerase chain reaction (RT-PCR) confirmed the diagnosis. Due to the neonate's critical lung involvement leading to a critical condition, remdesivir, intravenous immune globulin (IVIG) and corticosteroid were administered. The patient fully recovered and was discharged after around 20 days.
    Clinical discussion: Although treatment in most cases of neonatal COVID-19 has been mainly supportive, in a few case reports remdesivir, corticosteroids and IVIG have been successfully used. Since a satisfying clinical improvement was not noticed following sepsis workup, all the three aforementioned medications were administered.
    Conclusion: Immunomodulatory medications as well as antiviral therapy should be considered in severe neonatal COVID-19 cases, as were shown to be lifesaving in our patient. Interestingly, to date, this case seems to be the youngest survived patient who has received medicines other than supportive care.
    Sprache Englisch
    Erscheinungsdatum 2022-04-10
    Erscheinungsland Netherlands
    Dokumenttyp Case Reports
    ISSN 2210-2612
    ISSN 2210-2612
    DOI 10.1016/j.ijscr.2022.107065
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Clinical evaluation of nebulized verapamil in out-patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease.

    Fahimi, Fanak / Pourdowlat, Guitti / Behzadnia, Neda / Mostofi, Sahar Sadigh / Forough, Aida Sefidani / Parto, Omid / Esmaeili, Ayda

    The clinical respiratory journal

    2022  Band 16, Heft 12, Seite(n) 802–811

    Abstract: Objective: Chronic obstructive pulmonary disease (COPD) is associated with many health complications, including pulmonary hypertension (PH). Although oral calcium channel blockers have shown promising results in managing COPD-induced PH, significant ... ...

    Abstract Objective: Chronic obstructive pulmonary disease (COPD) is associated with many health complications, including pulmonary hypertension (PH). Although oral calcium channel blockers have shown promising results in managing COPD-induced PH, significant systemic side effects may limit their use in this population. Administering verapamil through nebulization can be an alternative approach. We aim to assess the possible therapeutic effects of verapamil inhalation in out-patients with pulmonary hypertension (PH) secondary to COPD.
    Methods: A double-blind, randomized placebo-controlled clinical trial was conducted. Patients with PH were randomly assigned to two groups of 15 participants. The intervention group received a short-term single dose of 10 mg nebulized verapamil (4 ampoules of 2.5 mg/ml verapamil solutions). The control group received nebulized distilled water as a placebo in addition to their standard treatment throughout the study.
    Results: Systolic pulmonary artery pressure (sPAP) did not improve as a primary outcome significantly in patients receiving nebulized verapamil compared with those on placebo (p = 0.89). Spirometry results showed a significant improvement in FVC in the intervention group from 1.72 ± 0.63 to 1.85 ± 0.58 L (p = 0.00), and FEV1/FVC ratio decreased significantly after verapamil administration (p = 0.027).
    Conclusion: Verapamil did not improve any of the pulmonary artery or RV parameters in patients with COPD-associated, but it did improve SpO
    Mesh-Begriff(e) Humans ; Forced Expiratory Volume ; Verapamil ; Hypertension, Pulmonary/drug therapy ; Hypertension, Pulmonary/etiology ; Outpatients ; Pulmonary Disease, Chronic Obstructive/complications ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Administration, Inhalation ; Double-Blind Method
    Chemische Substanzen Verapamil (CJ0O37KU29)
    Sprache Englisch
    Erscheinungsdatum 2022-11-06
    Erscheinungsland England
    Dokumenttyp Randomized Controlled Trial ; Journal Article
    ZDB-ID 2442214-9
    ISSN 1752-699X ; 1752-6981
    ISSN (online) 1752-699X
    ISSN 1752-6981
    DOI 10.1111/crj.13551
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang